Research Library › Distinct testing questions
Peptide purity, endotoxin testing, and sterility testing answer different questions. A certificate should identify which attribute was measured, the method used, and the sample tested. A strong result for one attribute does not automatically establish another.
Three attributes, three evidence questions
- Chromatographic purity: what distribution of detector response was reported under the stated analytical method?
- Bacterial endotoxins: what result was obtained with the stated endotoxin test and reporting basis?
- Sterility testing: was microbial growth detected in the tested samples under the stated test conditions?
Keep these entries separate in a material-review record. A purity chromatogram should not be described as a sterility test, and an endotoxin report should not be treated as a replacement for identity or quantitative-content evidence.
What does bacterial endotoxin refer to?
FDA’s technical guide describes bacterial endotoxins as lipopolysaccharides associated with the outer membrane of gram-negative bacteria [1]. This makes endotoxin a different analytical target from viable microorganisms. An endotoxin result and a sterility-test result therefore cannot be treated as interchangeable.
The cited FDA sources concern pharmaceutical or device testing. They are used here for terminology and measurement context, not to claim approval, clinical suitability, or compliance for Not Labs research materials.
Why does the endotoxin method matter?
FDA’s March 2026 guidance discusses test sensitivity and inhibition or enhancement when assessing endotoxin methods [2]. A result should be interpreted with the assay’s suitability for the tested material, rather than as a number detached from its method.
Record the result exactly as reported, including units, reporting basis, and any threshold or qualification. A value expressed per unit of volume is not automatically comparable with a value expressed per unit of mass. If a result is reported below a stated limit, preserve that qualification rather than rewriting it as zero.
What are the limits of a sterility test?
FDA’s aseptic-processing guidance explains that sterility testing has detection limitations related to sample size and emphasizes appropriate laboratory controls [3]. A passing test result should remain attached to its sampling plan and method. It does not mean that every unit in a lot was individually tested.
For documentation review, ask which samples were tested, how they represent the lot, and what supporting method information is available. Avoid converting a report’s conclusion into a broader claim than the records support.
What if a certificate lists purity only?
Record the reported purity and leave unreported attributes as “not reported.” The absence of an endotoxin or sterility entry is not a positive result, a negative result, or proof that testing occurred. If a protocol requires that attribute, resolve the documentation question before accepting the material for that application.
Conversely, additional testing does not replace the need to verify peptide identity or content. Use Purity vs Identity and Peptide Content vs Purity to review those separate questions.
A checklist for comparing reports
- Match the sample. Connect the compound, lot identifier, and tested material to the records being reviewed.
- Name the attribute. Keep purity, endotoxins, sterility, identity, and content in separate fields.
- Preserve context. Record method, units, limits, qualifications, and relevant sampling details.
- Define the requirement. Use the research protocol’s documented criteria; do not invent a universal acceptance threshold.
- Resolve gaps. Request missing evidence instead of inferring it from packaging, appearance, or general testing language.
Continue the evidence review
Read How to Read a Peptide COA and How to Compare Peptide Batches. Review Purity vs Potency for functional evidence. Visit Testing & Verification for the documentation supplied for research materials.
Technical references
- FDA. Bacterial Endotoxins/Pyrogens. Technical background.
- FDA (March 2026). Pyrogen and Endotoxins Testing: Questions and Answers.
- FDA (2004). Sterile Drug Products Produced by Aseptic Processing. Section XI discusses sterility-testing controls and limitations.